BACKGROUND: There is growing interest in determining the degree of anemia, which is clinically significant. The goal of this study was to determine the association between hemoglobin concentration and cognitive impairment in a large sample of U.S. adults. METHODS: We used cross-sectional data from 19,701 adults participating in the REasons for Geographic And Racial Differences in Stroke study. Cognitive impairment was defined as a score of 4 or less on the six-item screener. Hemoglobin was analyzed in 1 g/dL increments relative to the World Health Organization (WHO) threshold (<13 g/dL for men and <12 g/dL for women). RESULTS: The mean hemoglobin concentration was 13.7 ± 1.5 g/dL. The prevalence of cognitive impairment increased from 4.3% among individuals with a hemoglobin >3 g/dL above the WHO threshold to 16.8% for those with a hemoglobin ≥2 g/dL below the WHO threshold. After adjustment for demographics, chronic health conditions, health status, and inflammation, the association between reduced hemoglobin and cognitive impairment was attenuated and no longer significant, including among those with hemoglobin ≥2 g/dL below the WHO threshold (odds ratio 1.39, 95% confidence interval = 0.94-2.04). A test for linear trend was of borderline significance (p value = .06). For 94% of the sample within 2 g/dL of the WHO threshold, there was no relationship between hemoglobin concentration and the odds of cognitive impairment. The associations did not differ by sex and race. CONCLUSIONS: Within a large sample of community-dwelling adults, there was no significant association between hemoglobin concentration and cognitive impairment after multivariable adjustment.
BACKGROUND: There is growing interest in determining the degree of anemia, which is clinically significant. The goal of this study was to determine the association between hemoglobin concentration and cognitive impairment in a large sample of U.S. adults. METHODS: We used cross-sectional data from 19,701 adults participating in the REasons for Geographic And Racial Differences in Stroke study. Cognitive impairment was defined as a score of 4 or less on the six-item screener. Hemoglobin was analyzed in 1 g/dL increments relative to the World Health Organization (WHO) threshold (<13 g/dL for men and <12 g/dL for women). RESULTS: The mean hemoglobin concentration was 13.7 ± 1.5 g/dL. The prevalence of cognitive impairment increased from 4.3% among individuals with a hemoglobin >3 g/dL above the WHO threshold to 16.8% for those with a hemoglobin ≥2 g/dL below the WHO threshold. After adjustment for demographics, chronic health conditions, health status, and inflammation, the association between reduced hemoglobin and cognitive impairment was attenuated and no longer significant, including among those with hemoglobin ≥2 g/dL below the WHO threshold (odds ratio 1.39, 95% confidence interval = 0.94-2.04). A test for linear trend was of borderline significance (p value = .06). For 94% of the sample within 2 g/dL of the WHO threshold, there was no relationship between hemoglobin concentration and the odds of cognitive impairment. The associations did not differ by sex and race. CONCLUSIONS: Within a large sample of community-dwelling adults, there was no significant association between hemoglobin concentration and cognitive impairment after multivariable adjustment.
Authors: Paulo H M Chaves; Michelle C Carlson; Luigi Ferrucci; Jack M Guralnik; Richard Semba; Linda P Fried Journal: J Am Geriatr Soc Date: 2006-09 Impact factor: 5.562
Authors: Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard Journal: Neuroepidemiology Date: 2005-06-29 Impact factor: 3.282
Authors: G Metry; B Wikström; S Valind; B Sandhagen; T Linde; S Beshara; B Långström; B G Danielson Journal: J Am Soc Nephrol Date: 1999-04 Impact factor: 10.121
Authors: C Barrett Bowling; Paul Muntner; Brian D Bradbury; Ryan D Kilpatrick; John J Isitt; Amy H Warriner; Jeffrey R Curtis; Suzanne Judd; Cynthia J Brown; Richard M Allman; David G Warnock; William McClellan Journal: Am J Med Sci Date: 2013-06 Impact factor: 2.378
Authors: Neil A Zakai; Benjamin French; Alice M Arnold; Anne B Newman; Linda F Fried; John Robbins; Paulo Chaves; Mary Cushman Journal: Am J Hematol Date: 2012-10-09 Impact factor: 10.047
Authors: Andrea L C Schneider; Charles Jonassaint; A Richey Sharrett; Thomas H Mosley; Brad C Astor; Elizabeth Selvin; Josef Coresh; Rebecca F Gottesman Journal: J Gerontol A Biol Sci Med Sci Date: 2015-09-11 Impact factor: 6.053
Authors: Lee Hooper; Asmaa Abdelhamid; Natalie J Attreed; Wayne W Campbell; Adam M Channell; Philippe Chassagne; Kennith R Culp; Stephen J Fletcher; Matthew B Fortes; Nigel Fuller; Phyllis M Gaspar; Daniel J Gilbert; Adam C Heathcote; Mohannad W Kafri; Fumiko Kajii; Gregor Lindner; Gary W Mack; Janet C Mentes; Paolo Merlani; Rowan A Needham; Marcel G M Olde Rikkert; Andreas Perren; James Powers; Sheila C Ranson; Patrick Ritz; Anne M Rowat; Fredrik Sjöstrand; Alexandra C Smith; Jodi J D Stookey; Nancy A Stotts; David R Thomas; Angela Vivanti; Bonnie J Wakefield; Nana Waldréus; Neil P Walsh; Sean Ward; John F Potter; Paul Hunter Journal: Cochrane Database Syst Rev Date: 2015-04-30